UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
27 mars 2023 07h30 HE
|
Unity Biotechnology, Inc.
UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with...
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
15 mars 2023 16h05 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
28 févr. 2023 16h05 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
UNITY Biotechnology to Participate in the SVB Securities Global Biopharma Conference
15 févr. 2023 08h00 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
UNITY Biotechnology to Host Investor Call to Review Data from the UBX1325 Program and Provide an Overview of the ENVISION Wet AMD Study
09 févr. 2023 08h00 HE
|
Unity Biotechnology, Inc.
-Investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., to be held on Tuesday, February 14, 2023 at 7:00 a.m. PT/ 10:00 a.m. ET- -Complete 16- and 24-week safety and efficacy data from...
UNITY Biotechnology Reports Granting of New Employment Inducement Award
18 janv. 2023 08h00 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates
08 nov. 2022 16h10 HE
|
Unity Biotechnology, Inc.
- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in...
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
01 nov. 2022 07h00 HE
|
Unity Biotechnology, Inc.
A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment ...
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
31 oct. 2022 18h11 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or...
UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today
19 oct. 2022 08h30 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt or...